Results 191 to 200 of about 824,117 (206)

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

Science, 1997
G. Simmons, P. Clapham, L. Picard, R. Offord, M. Rosenkilde, T. Schwartz, R. Buser, T. Wells, A. Proudfoot   +8 more
semanticscholar   +1 more source

Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist

ACS Medicinal Chemistry Letters, 2010
Thomas Wisniewski, Julia M Ayala, Jerry di Salvo   +2 more
exaly  

A dual CCR2/CCR5 chemokine antagonist, BMS-813160?

Expert Opinion on Therapeutic Patents, 2011
Peter Norman
exaly  

Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc

Bioorganic and Medicinal Chemistry Letters, 2010
Andreas Jekle, Gabrielle Heilek, Changhua Ji   +2 more
exaly  

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Nature Medicine, 2005
G. Fätkenheuer, A. Pozniak, Margaret A. Johnson, A. Plettenberg, S. Staszewski, A. Hoepelman, M. Saag, F. Goebel, J. Rockstroh, B. Dezube, T. Jenkins, C. Medhurst, J. Sullivan, C. Ridgway, S. Abel, Ian T. James, M. Youle, E. van der Ryst   +17 more
semanticscholar   +1 more source

Treatment of HIV infection with the CCR5 antagonist maraviroc

Expert Opinion on Pharmacotherapy, 2010
Alwin Dr Huitema, Jan Willem Mulder
exaly  

Determination of nifeviroc, a novel CCR5 antagonist: Application to a pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis, 2011
Zeneng Cheng
exaly  

Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection

Expert Opinion on Pharmacotherapy, 2008
Jeffery D Evans
exaly  

Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection

Clinical Therapeutics, 2008
Juan C Bandres
exaly  

Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity

ACS Medicinal Chemistry Letters, 2010
Douglas Keller, Swamy Yeleswaram, Sharon Diamond   +2 more
exaly